Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 16, 2017Clinical Pharmacology in Drug Development

The Effect of Verapamil, a P‐Glycoprotein Inhibitor, on the Pharmacokinetics of Peficitinib, an Orally Administered, Once‐Daily JAK Inhibitor

View Full Paper
Ask AI
Bookmark
Share

Authors

TZTong ZhuCapital Medical UniversityCHCorrie HowiesonAstellas Pharma (United States)TWTomasz WojtkowskiAstellas Pharma (United States)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Zhu et al. (2017) studied this question.

synapsesocial.com/papers/6aa4e20751c745fa0f283d97https://doi.org/10.1002/cpdd.344
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pharmacokinetics of Verapamil and Norverapamil Enantiomers After Administration of Immediate and Controlled‐Release Formulations to Humans: Evidence Suggesting Input‐Rate Determined Stereoselectivity1995 · 12 citations
  2. 2Multiple Drug Transport Pathways through Human P-Glycoprotein2015 · 82 citations
  3. 3A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis2015 · 118 citations
  4. 4Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study2015 · 150 citations